Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here . The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. The SP500TR and R2000 returned approximately 15.0% and 21.5%, respectively, in the second quarter. The impressive performance was driven by three of the top five positions being acquired, with its largest position nearly doubling during the quarter. The letter emphasizes that patience can often lead to profits in an inefficient market characterized by fluctuations, suggesting that investing in undervalued stocks can yield good long-term returns. In addition, please check the portfolio's top five holdings to know its best picks in 2026.

In its Q2 2026 investor letter, Laughing Water Capital highlighted Lifecore Biomedical, Inc. (NASDAQ: LFCR ). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization that engages in the aseptic fill and finish of formulations and highly viscous sterile injectable pharmaceutical drug and medical device products. On July 14, 2026, Lifecore Biomedical, Inc. (NASDAQ:LFCR) closed at $4.61 per share, reflecting a market capitalization of $172.92 million. Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted a one-month return of -16.49%, while its shares lost 39.97% over the past 52 weeks.

Laughing Water Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its Q2 2026 investor update:

"Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Lifecore, our under-utilized fill-finish Contract Drug Manufacturing Organization, continues to win new business at an impressive rate, and the market continues to not care. I continue to believe that when the new business wins translate into revenue the operating leverage will be massive, and Lifecore will generate significant cash. Of note, following the end of the quarter the company issued an 8K noting that holders of Series A Preferred Stock were redeeming their shares, and also that the company is evaluating strategic alternatives. I think that a sale of the company is likely in the not-too-distant future."

Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 . According to our database, 17 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the first quarter, compared to 19 in the previous quarter. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

In another article , we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Laughing Water Capital's insights on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .

Disclosure: None. This article is originally published at Insider Monkey .

Sinergia Empresarial continuará el seguimiento de esta información sobre lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.